Cargando…

Mining Natural Products for Macrocycles to Drug Difficult Targets

[Image: see text] Lead generation for difficult-to-drug targets that have large, featureless, and highly lipophilic or highly polar and/or flexible binding sites is highly challenging. Here, we describe how cores of macrocyclic natural products can serve as a high-quality in silico screening library...

Descripción completa

Detalles Bibliográficos
Autores principales: Begnini, Fabio, Poongavanam, Vasanthanathan, Over, Björn, Castaldo, Marie, Geschwindner, Stefan, Johansson, Patrik, Tyagi, Mohit, Tyrchan, Christian, Wissler, Lisa, Sjö, Peter, Schiesser, Stefan, Kihlberg, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872424/
https://www.ncbi.nlm.nih.gov/pubmed/33337880
http://dx.doi.org/10.1021/acs.jmedchem.0c01569
_version_ 1783649182703157248
author Begnini, Fabio
Poongavanam, Vasanthanathan
Over, Björn
Castaldo, Marie
Geschwindner, Stefan
Johansson, Patrik
Tyagi, Mohit
Tyrchan, Christian
Wissler, Lisa
Sjö, Peter
Schiesser, Stefan
Kihlberg, Jan
author_facet Begnini, Fabio
Poongavanam, Vasanthanathan
Over, Björn
Castaldo, Marie
Geschwindner, Stefan
Johansson, Patrik
Tyagi, Mohit
Tyrchan, Christian
Wissler, Lisa
Sjö, Peter
Schiesser, Stefan
Kihlberg, Jan
author_sort Begnini, Fabio
collection PubMed
description [Image: see text] Lead generation for difficult-to-drug targets that have large, featureless, and highly lipophilic or highly polar and/or flexible binding sites is highly challenging. Here, we describe how cores of macrocyclic natural products can serve as a high-quality in silico screening library that provides leads for difficult-to-drug targets. Two iterative rounds of docking of a carefully selected set of natural-product-derived cores led to the discovery of an uncharged macrocyclic inhibitor of the Keap1-Nrf2 protein–protein interaction, a particularly challenging target due to its highly polar binding site. The inhibitor displays cellular efficacy and is well-positioned for further optimization based on the structure of its complex with Keap1 and synthetic access. We believe that our work will spur interest in using macrocyclic cores for in silico-based lead generation and also inspire the design of future macrocycle screening collections.
format Online
Article
Text
id pubmed-7872424
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-78724242021-02-10 Mining Natural Products for Macrocycles to Drug Difficult Targets Begnini, Fabio Poongavanam, Vasanthanathan Over, Björn Castaldo, Marie Geschwindner, Stefan Johansson, Patrik Tyagi, Mohit Tyrchan, Christian Wissler, Lisa Sjö, Peter Schiesser, Stefan Kihlberg, Jan J Med Chem [Image: see text] Lead generation for difficult-to-drug targets that have large, featureless, and highly lipophilic or highly polar and/or flexible binding sites is highly challenging. Here, we describe how cores of macrocyclic natural products can serve as a high-quality in silico screening library that provides leads for difficult-to-drug targets. Two iterative rounds of docking of a carefully selected set of natural-product-derived cores led to the discovery of an uncharged macrocyclic inhibitor of the Keap1-Nrf2 protein–protein interaction, a particularly challenging target due to its highly polar binding site. The inhibitor displays cellular efficacy and is well-positioned for further optimization based on the structure of its complex with Keap1 and synthetic access. We believe that our work will spur interest in using macrocyclic cores for in silico-based lead generation and also inspire the design of future macrocycle screening collections. American Chemical Society 2020-12-18 2021-01-28 /pmc/articles/PMC7872424/ /pubmed/33337880 http://dx.doi.org/10.1021/acs.jmedchem.0c01569 Text en © 2020 American Chemical Society This is an open access article published under a Creative Commons Attribution (CC-BY) License (http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html) , which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
spellingShingle Begnini, Fabio
Poongavanam, Vasanthanathan
Over, Björn
Castaldo, Marie
Geschwindner, Stefan
Johansson, Patrik
Tyagi, Mohit
Tyrchan, Christian
Wissler, Lisa
Sjö, Peter
Schiesser, Stefan
Kihlberg, Jan
Mining Natural Products for Macrocycles to Drug Difficult Targets
title Mining Natural Products for Macrocycles to Drug Difficult Targets
title_full Mining Natural Products for Macrocycles to Drug Difficult Targets
title_fullStr Mining Natural Products for Macrocycles to Drug Difficult Targets
title_full_unstemmed Mining Natural Products for Macrocycles to Drug Difficult Targets
title_short Mining Natural Products for Macrocycles to Drug Difficult Targets
title_sort mining natural products for macrocycles to drug difficult targets
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872424/
https://www.ncbi.nlm.nih.gov/pubmed/33337880
http://dx.doi.org/10.1021/acs.jmedchem.0c01569
work_keys_str_mv AT begninifabio miningnaturalproductsformacrocyclestodrugdifficulttargets
AT poongavanamvasanthanathan miningnaturalproductsformacrocyclestodrugdifficulttargets
AT overbjorn miningnaturalproductsformacrocyclestodrugdifficulttargets
AT castaldomarie miningnaturalproductsformacrocyclestodrugdifficulttargets
AT geschwindnerstefan miningnaturalproductsformacrocyclestodrugdifficulttargets
AT johanssonpatrik miningnaturalproductsformacrocyclestodrugdifficulttargets
AT tyagimohit miningnaturalproductsformacrocyclestodrugdifficulttargets
AT tyrchanchristian miningnaturalproductsformacrocyclestodrugdifficulttargets
AT wisslerlisa miningnaturalproductsformacrocyclestodrugdifficulttargets
AT sjopeter miningnaturalproductsformacrocyclestodrugdifficulttargets
AT schiesserstefan miningnaturalproductsformacrocyclestodrugdifficulttargets
AT kihlbergjan miningnaturalproductsformacrocyclestodrugdifficulttargets